🔗 Share this article

Given that America undertakes sweeping changes to its vaccination schedules, one figure appears unexpectedly: Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by casting doubt on Covid vaccinations in the global health crisis and has focused upon potential deaths after Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Immunization Program

Public health authorities had intended to announce major changes to the childhood vaccine schedule recently, bringing the US with Denmark’s immunization schedule, sources say – a major change that would place the US out of step with many the world with insufficient data for improved outcomes. The planned update has been pushed back until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to lead the division this calendar year.

A New Direction at the Regulatory Body

The acting appointment could signify a strengthened alliance between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a increased emphasis upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing certain pediatric immunization guidelines in the US to become more like Denmark, a nation with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

To date statements, she has kept her attention on vaccines – typically the purview of Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Qualifications

The appointee has little discernible experience in pharmaceutical research, oversight or leadership, which has been customary for past directors of the biologics center. She has served at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for overseeing the CDER, remarked a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in running a sizeable institution. She is not an expert in industry regulation.”

Previous heads of CBER would “understand legal statutes and the science of pharmaceutical innovation”, said Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who ran CBER have had.”

The drug center has an immense portfolio at the agency, she stated.

“Many people just focuses on the novel medication approvals, but the generic drug division authorizes thousands of generic drugs. There is also a biosimilars program, over-the-counter program and more, and each of these need to be looked after,” Woodcock said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a major management element to the job, which oversees in excess of 5,000 personnel. “It is a massive leadership role, if you execute it properly,” she said.

Official Statement and Disputed Policies

In response to questions about Dr. Høeg's qualifications and whether this selection indicates more teamwork among regulatory chiefs on vaccines, a press secretary responded that the “questions stem from flawed assumptions”.

“Her experience is consistent with the responsibilities of her job,” the official stated, pointing to the months Høeg spent counseling the agency head on “drug safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg takes over the commissioner’s controversial expedited review system, a disputed one-day therapy clearance system that reportedly concerned her preceding directors. “How are these drugs being selected for this voucher program? Who makes the calls?” Dr. Howard asked. “There’s a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards more relaxed oversight of all drugs, except for vaccines.”

Established History on Vaccines

Concerning vaccines, Dr. Høeg has a clearer, if troubling, track record, Howard said. She authored a study using non-validated volunteer-provided data to estimate the rate of heart inflammation following Covid immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the incoming federal leadership included changing guidelines for recently developed shots and halting “optional” immunizations, she said post-election on a online show. At the FDA, Høeg has allegedly floated the idea of preventing adolescent males from obtaining COVID-19 vaccines.

“She’s an all-around ideologue who starts off with her conclusions and tailors the evidence to retrofit the science in a highly disingenuous, untruthful way,” Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|